No-Fingersticks* For Treatment Decisions
Stay on top of your diabetes management knowing you get exceptionally accurate1 readings, even with hypoglycemia, and learn how to use trend arrows.
There are 5 different trend arrows that show the current direction of your glucose levels, and how fast they are changing. The app uses the last 20 minutes of continuous glucose data for calculating glucose trends.
|
|
|
Let's see an example of a situation you may encounter. It's important to consider what has happened and what is about to happen when using Eversense E3 CGM to make treatment decisions.
Glucose below target at 75 mg/dL but rising moderately. Your glucose could rise between 30 and 60 mg/dL and could reach 135 mg/dL (75 plus 60) within 30 minutes.
It’s 9am, and you dosed insulin for your breakfast about 2 hours ago.
Feel confident using your Eversense E3 CGM data to make treatment decisions.
Before making a treatment decision from your CGM data**, you should take into account the sensor glucose value, the trend arrow, the trend graph, and any alerts from the Eversense E3 CGM System. You should not base your decisions on glucose value only or trend arrow only.
Eversense E3 CGM can be your trusted companion supporting you not only on insulin dosing decisions, but also on type and size of meals as well as on planning and undertaking physical activity.
If in doubt, please discuss with your health care provider about how to manage insulin dosing for different types of food, and how to accurately calculate carbohydrates.
You can count on your Eversense E3 CGM data to respond reactively and with confidence, knowing that it remains highly accurate1, even with hypoglycemia, throughout the 6 month period.
And it is proven to detect high glucose levels correctly 99% of the time (180 mg/dL) and low glucose levels correctly 94% of the time (70 mg/dL).1
Stay in the know with the Eversense E3 and get helpful pointers on how to manage your diabetes wi...
Learn how to set up and calibrate your system to start getting your glucose data and the most acc...
Find out how the Eversense E3 Smart Transmitter is designed to work the way you need and to be wo...
Trend Arrows And Treatment Decisions >
Stay on top of your diabetes management knowing you get exceptionally accurate1 readings, even wi...
Access your In-App Reports in the Eversense App to better understand your glucose patterns and hi...
Low And High Alerts, And Targets >
The Eversense E3 CGM System is designed to provide ON-BODY VIBRATION alerts through your smart tr...
Predictive And Rate of Change Alerts >
Even with the best management plan, diabetes can still be unpredictable at times. In addition to ...
Keep tabs on your glucose levels over time and share this information, to help you and your healt...
E3 Long Term Exceptional Accuracy >
There is no other CGM system available today to offer such exceptional accuracy with a single sen...
Taking care of family and friends, performing at work each day, challenging yourself with sports,...
When getting ready for traveling with diabetes, there is so much to think of, isn’t it? Of ...
Get Ready For Your Next E3 Sensor >
Preparing for your next sensor in advance will ensure a smooth and uninterrupted experience.
* Fingersticks are still required for calibration and when symptoms do not match readings, or while taking medications of the tetracycline class.
** There are other things you should also take into account such as eating, insulin and medication administration, and timing. Please consult your health care provider for personalized advice.
1. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1-9. DOI:10.1089/dia.2021.0182.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
